Glioblastoma is the most common and aggressive brain tumor, associated with poor prognosis and survival, representing a challenging medical issue for neurooncologists. Dysregulation of histone-modifying enzymes (HDACs) is commonly identified in many tumors and has been linked to cancer proliferation, changes in metabolism, and drug resistance. These findings led to the development of HDAC inhibitors, which are limited by their narrow therapeutic index. In this work, we provide the proof of concept for a delivery system that can improve the in vivo half-life and increase the brain delivery of Givinostat, a pan-HDAC inhibitor. Here, 150-nm-sized liposomes composed of cholesterol and sphingomyelin with or without surface decoration with mApoE peptide, inhibited human glioblastoma cell growth in 2D and 3D models by inducing a time-and dose-dependent reduction in cell viability, reduction in the receptors involved in cholesterol metabolism (from −25% to −75% of protein levels), and reduction in HDAC activity (−25% within 30 min). In addition, liposome-Givinostat formulations showed a 2.5-fold increase in the drug half-life in the bloodstream and a 6-fold increase in the amount of drug entering the brain in healthy mice, without any signs of overt toxicity. These features make liposomes loaded with Givinostat valuable as potential candidates for glioblastoma therapy.

Taiarol, L., Bigogno, C., Sesana, S., Kravicz, M., Viale, F., Pozzi, E., et al. (2022). Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics. CANCERS, 14(12) [10.3390/cancers14122978].

Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics

Taiarol, Lorenzo
Primo
;
Sesana, Silvia;Kravicz, Marcelo;Viale, Francesca;Pozzi, Eleonora;Monza, Laura;Carozzi, Valentina Alda;Meregalli, Cristina;Moresco, Rosa Maria;Barbugian, Federica;Russo, Laura;Re, Francesca
Ultimo
2022

Abstract

Glioblastoma is the most common and aggressive brain tumor, associated with poor prognosis and survival, representing a challenging medical issue for neurooncologists. Dysregulation of histone-modifying enzymes (HDACs) is commonly identified in many tumors and has been linked to cancer proliferation, changes in metabolism, and drug resistance. These findings led to the development of HDAC inhibitors, which are limited by their narrow therapeutic index. In this work, we provide the proof of concept for a delivery system that can improve the in vivo half-life and increase the brain delivery of Givinostat, a pan-HDAC inhibitor. Here, 150-nm-sized liposomes composed of cholesterol and sphingomyelin with or without surface decoration with mApoE peptide, inhibited human glioblastoma cell growth in 2D and 3D models by inducing a time-and dose-dependent reduction in cell viability, reduction in the receptors involved in cholesterol metabolism (from −25% to −75% of protein levels), and reduction in HDAC activity (−25% within 30 min). In addition, liposome-Givinostat formulations showed a 2.5-fold increase in the drug half-life in the bloodstream and a 6-fold increase in the amount of drug entering the brain in healthy mice, without any signs of overt toxicity. These features make liposomes loaded with Givinostat valuable as potential candidates for glioblastoma therapy.
Articolo in rivista - Articolo scientifico
Scientifica
brain; cancer; glioblastoma; HDAC inhibitor; liposomes;
English
Taiarol, L., Bigogno, C., Sesana, S., Kravicz, M., Viale, F., Pozzi, E., et al. (2022). Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics. CANCERS, 14(12) [10.3390/cancers14122978].
Taiarol, L; Bigogno, C; Sesana, S; Kravicz, M; Viale, F; Pozzi, E; Monza, L; Carozzi, V; Meregalli, C; Valtorta, S; Moresco, R; Koch, M; Barbugian, F; Russo, L; Dondio, G; Steinkühler, C; Re, F
File in questo prodotto:
File Dimensione Formato  
cancers-14-02978.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 3.49 MB
Formato Adobe PDF
3.49 MB Adobe PDF Visualizza/Apri
cancers-1697072_supplementary_file.pdf

accesso aperto

Descrizione: Supplementary files
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 2.47 MB
Formato Adobe PDF
2.47 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/385482
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact